OMX Ventures invests across tools, diagnostics, and therapeutics because "tools lead to new insights that lead to new products." This strategy provides a "front row seat" to emerging technologies, allowing them to understand a new tool's power and application before the broader market. This information arbitrage leads to smarter investments across their entire portfolio.
While a first fund is raised on a compelling vision, raising a second requires demonstrating institutional maturity. LPs shift from underwriting a founder's promise to underwriting a firm's ability to be "consistently excellent." The narrative must evolve to highlight repeatable processes, refined decision frameworks, and a scalable organizational structure.
OMX Ventures defines its role not as a shadow operator but as a partner helping founders "see around corners." While founders are consumed by short-term execution (the next month or quarter), the VC's responsibility is to maintain a long-term perspective, looking a few years down the road to guide strategic thinking and ensure alignment.
The market correctly sees biology's potential but often misunderstands its timeline. Even with AI, biology is fundamentally harder and slower than software. Daniel Fero warns this mismatch in "tempo" expectations leads to over-funding hype cycles while under-funding foundational companies that are simply moving at the pace required for rigorous biological R&D.
When raising a first fund, you sell a future vision. To make this tangible, OMX Ventures leveraged founders they had previously supported. These founders served not only as powerful references but also became Limited Partners (LPs) in the new fund, providing the ultimate validation of the VC's value-add and building a loyal capital base.
Beyond the thesis, first-time biotech funds must explicitly align with LPs on the 6-to-9-year journey from seed to exit. Daniel Fero stresses finding LPs who understand their capital will be locked up for a long duration, unlike in crossover funds with shorter horizons. This "psychological fit" on capital flow expectations is crucial for a stable fund.